{"success":true,"data":{"pressRelease":{"id":"3053","rtpr_id":"nGNXfN6n2","ticker":"CRDF","exchange":"NASDAQ","all_tickers":["CRDF"],"title":"Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026","author":"Globe Newswire","published_at":"2026-04-21T14:00:00.436Z","article_body":"SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq:\nCRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to\ndevelop novel cancer therapies, today announced it will present updated data\nfrom CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating\nonvansertib in combination with standard of care (SoC) regimens\n(FOLFIRI/bevacizumab (bev) or FOLFOX/bev) in patients with first-line\nRAS-mutated metastatic colorectal cancer (mCRC). The data will be reviewed in\na rapid oral presentation at the 2026 American Society of Clinical Oncology\n(ASCO) Annual Meeting, taking place May 29–June 2 in Chicago.\n\nRapid Oral Presentation Details:\n\nAbstract Title: Onvansertib plus standard-of-care chemotherapy plus\nbevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC):\nInterim results from the phase 2 randomized CRDF-004 trial\nAbstract Number: 3510  \nSession Title: Gastrointestinal Cancer—Colorectal and Anal \nSession Date and Time: June 2, 2026, 8:00-9:30 AM CDT  \n\nThe abstract will be publicly available on Thursday, May 21, 2026 on ASCO’s\nwebsite, and the presentation will be made available on the Scientific\nPublications page of the Company’s website following its presentation.\n\nAbout Onvansertib\nOnvansertib is a highly specific, oral PLK1 inhibitor currently in mid-stage\nclinical development for RAS-mutated metastatic colorectal cancer. It is also\nbeing evaluated in multiple other cancers through investigator-initiated\nstudies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small\ncell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic\nmyelomonocytic leukemia (CMML).\n\nAbout Cardiff Oncology, Inc. \nCardiff Oncology is a clinical-stage biotechnology company advancing\ninnovative cancer treatments focused on PLK1 inhibition, a validated oncology\ntarget with practice-changing potential. Our lead asset, onvansertib, is a\nhighly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2\ntrial for first-line treatment of RAS-mutated metastatic colorectal cancer\n(mCRC), addressing a large, underserved patient population with high unmet\nneed. Onvansertib is also under investigation in other PLK1-driven cancers\nthrough ongoing investigator-initiated trials and has shown robust single\nagent clinical activity in hard-to-treat tumors. By targeting tumor\nvulnerabilities, we aim to overcome treatment resistance and deliver improved\nclinical outcomes for patients.\n\nFor more information, please visit https://www.cardiffoncology.com.\n\nForward-Looking Statements \nCertain statements in this press release are forward-looking within the\nmeaning of the Private Securities Litigation Reform Act of 1995. These\nstatements may be identified using words such as \"anticipate,\" \"believe,\"\n\"forecast,\" \"estimated\" and \"intend\" or other similar terms or expressions\nthat concern Cardiff Oncology's expectations, strategy, plans or intentions.\nThese forward-looking statements are based on Cardiff Oncology's\ncurrent expectations and actual results could differ materially. There are\nseveral factors that could cause actual events to differ materially from\nthose indicated by such forward-looking statements. These factors include,\nbut are not limited to, clinical trials involve a lengthy and expensive\nprocess with an uncertain outcome, and results of earlier studies and trials\nmay not be predictive of future trial results; our clinical trials may be\nsuspended or discontinued due to unexpected side effects or other safety risks\nthat could preclude approval of our product candidate; results of preclinical\nstudies or clinical trials for our product candidate could be unfavorable or\ndelayed; our need for additional financing; risks related to business\ninterruptions, including the outbreak of COVID-19 coronavirus and\ncyber-attacks on our information technology infrastructure, which could\nseriously harm our financial condition and increase our costs and expenses;\nuncertainties of government or third party payer reimbursement; dependence on\nkey personnel; limited experience in marketing and sales; substantial\ncompetition; uncertainties of patent protection and litigation; dependence\nupon third parties; and risks related to failure to obtain FDA clearances or\napprovals and noncompliance with FDA regulations. There are no guarantees that\nour product candidate will be utilized or prove to be commercially\nsuccessful. Additionally, there are no guarantees that future clinical trials\nwill be completed or successful or that our product candidate will receive\nregulatory approval for any indication or prove to be commercially\nsuccessful. Investors should read the risk factors set forth in Cardiff\nOncology's Form 10-K for the year ended December 31, 2025, and other periodic\nreports filed with the Securities and Exchange Commission. While the list of\nfactors presented here is considered representative, no such list should be\nconsidered to be a complete statement of all potential risks and\nuncertainties. Unlisted factors may present significant additional obstacles\nto the realization of forward-looking statements. Forward-looking statements\nincluded herein are made as of the date hereof, and Cardiff Oncology does\nnot undertake any obligation to update publicly such statements to\nreflect subsequent events or circumstances.\n\nInvestor Contact: \nCandice Masse \nastr partners \ncandice.masse@astrpartners.com\n\nMedia Contact: \nAmy Bonanno \nLyra Strategic Advisory \nabonanno@lyraadvisory.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/916adb81-8173-4fbe-8095-c284c4f44cd3)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXfN6n2","title":"Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026","author":"Globe Newswire","ticker":"CRDF","created":"2026-04-21T14:00:00.436Z","tickers":["CRDF"],"exchange":"NASDAQ","article_body":"SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq:\nCRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to\ndevelop novel cancer therapies, today announced it will present updated data\nfrom CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating\nonvansertib in combination with standard of care (SoC) regimens\n(FOLFIRI/bevacizumab (bev) or FOLFOX/bev) in patients with first-line\nRAS-mutated metastatic colorectal cancer (mCRC). The data will be reviewed in\na rapid oral presentation at the 2026 American Society of Clinical Oncology\n(ASCO) Annual Meeting, taking place May 29–June 2 in Chicago.\n\nRapid Oral Presentation Details:\n\nAbstract Title: Onvansertib plus standard-of-care chemotherapy plus\nbevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC):\nInterim results from the phase 2 randomized CRDF-004 trial\nAbstract Number: 3510  \nSession Title: Gastrointestinal Cancer—Colorectal and Anal \nSession Date and Time: June 2, 2026, 8:00-9:30 AM CDT  \n\nThe abstract will be publicly available on Thursday, May 21, 2026 on ASCO’s\nwebsite, and the presentation will be made available on the Scientific\nPublications page of the Company’s website following its presentation.\n\nAbout Onvansertib\nOnvansertib is a highly specific, oral PLK1 inhibitor currently in mid-stage\nclinical development for RAS-mutated metastatic colorectal cancer. It is also\nbeing evaluated in multiple other cancers through investigator-initiated\nstudies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small\ncell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic\nmyelomonocytic leukemia (CMML).\n\nAbout Cardiff Oncology, Inc. \nCardiff Oncology is a clinical-stage biotechnology company advancing\ninnovative cancer treatments focused on PLK1 inhibition, a validated oncology\ntarget with practice-changing potential. Our lead asset, onvansertib, is a\nhighly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2\ntrial for first-line treatment of RAS-mutated metastatic colorectal cancer\n(mCRC), addressing a large, underserved patient population with high unmet\nneed. Onvansertib is also under investigation in other PLK1-driven cancers\nthrough ongoing investigator-initiated trials and has shown robust single\nagent clinical activity in hard-to-treat tumors. By targeting tumor\nvulnerabilities, we aim to overcome treatment resistance and deliver improved\nclinical outcomes for patients.\n\nFor more information, please visit https://www.cardiffoncology.com.\n\nForward-Looking Statements \nCertain statements in this press release are forward-looking within the\nmeaning of the Private Securities Litigation Reform Act of 1995. These\nstatements may be identified using words such as \"anticipate,\" \"believe,\"\n\"forecast,\" \"estimated\" and \"intend\" or other similar terms or expressions\nthat concern Cardiff Oncology's expectations, strategy, plans or intentions.\nThese forward-looking statements are based on Cardiff Oncology's\ncurrent expectations and actual results could differ materially. There are\nseveral factors that could cause actual events to differ materially from\nthose indicated by such forward-looking statements. These factors include,\nbut are not limited to, clinical trials involve a lengthy and expensive\nprocess with an uncertain outcome, and results of earlier studies and trials\nmay not be predictive of future trial results; our clinical trials may be\nsuspended or discontinued due to unexpected side effects or other safety risks\nthat could preclude approval of our product candidate; results of preclinical\nstudies or clinical trials for our product candidate could be unfavorable or\ndelayed; our need for additional financing; risks related to business\ninterruptions, including the outbreak of COVID-19 coronavirus and\ncyber-attacks on our information technology infrastructure, which could\nseriously harm our financial condition and increase our costs and expenses;\nuncertainties of government or third party payer reimbursement; dependence on\nkey personnel; limited experience in marketing and sales; substantial\ncompetition; uncertainties of patent protection and litigation; dependence\nupon third parties; and risks related to failure to obtain FDA clearances or\napprovals and noncompliance with FDA regulations. There are no guarantees that\nour product candidate will be utilized or prove to be commercially\nsuccessful. Additionally, there are no guarantees that future clinical trials\nwill be completed or successful or that our product candidate will receive\nregulatory approval for any indication or prove to be commercially\nsuccessful. Investors should read the risk factors set forth in Cardiff\nOncology's Form 10-K for the year ended December 31, 2025, and other periodic\nreports filed with the Securities and Exchange Commission. While the list of\nfactors presented here is considered representative, no such list should be\nconsidered to be a complete statement of all potential risks and\nuncertainties. Unlisted factors may present significant additional obstacles\nto the realization of forward-looking statements. Forward-looking statements\nincluded herein are made as of the date hereof, and Cardiff Oncology does\nnot undertake any obligation to update publicly such statements to\nreflect subsequent events or circumstances.\n\nInvestor Contact: \nCandice Masse \nastr partners \ncandice.masse@astrpartners.com\n\nMedia Contact: \nAmy Bonanno \nLyra Strategic Advisory \nabonanno@lyraadvisory.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/916adb81-8173-4fbe-8095-c284c4f44cd3)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-21T14:00:00.493080612Z","server_sent_at_ms":1776780000493},"received_at":"2026-04-21T14:00:00.549Z","source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278117/0/en/cardiff-oncology-to-present-updated-phase-2-data-of-onvansertib-in-first-line-ras-mutated-mcrc-in-a-rapid-oral-session-at-asco-2026.html"},"analysis":{"id":"1997","press_release_id":"3053","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Cardiff Oncology announced that updated Phase 2 data from the CRDF-004 trial evaluating onvansertib in first-line RAS-mutated metastatic colorectal cancer will be presented at the 2026 ASCO Annual Meeting.\n\nThe data will be featured in a rapid oral presentation scheduled for June 2, 2026, covering interim results from the randomized dose-finding study combining the PLK1 inhibitor with standard-of-care regimens.\n\nThe abstract will be made publicly available on May 21, 2026, ahead of the conference.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"ASCO oral presentation validates data interest, but specific readout is still pending."},"namedEntities":{"people":[],"products":["Onvansertib","FOLFIRI/bevacizumab","FOLFOX/bevacizumab"],"companies":[{"name":"American Society of Clinical Oncology","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Selection for a rapid oral presentation at ASCO is a positive visibility signal, but the announcement contains no efficacy or safety data to drive material price action."},"tickerRelevance":{"others":[],"primary":"CRDF"},"eventTypeSecondary":[]},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Cardiff Oncology announced that updated Phase 2 data from the CRDF-004 trial evaluating onvansertib in first-line RAS-mutated metastatic colorectal cancer will be presented at the 2026 ASCO Annual Meeting.\n\nThe data will be featured in a rapid oral presentation scheduled for June 2, 2026, covering interim results from the randomized dose-finding study combining the PLK1 inhibitor with standard-of-care regimens.\n\nThe abstract will be made publicly available on May 21, 2026, ahead of the conference.","key_figures":null,"named_entities":{"people":[],"products":["Onvansertib","FOLFIRI/bevacizumab","FOLFOX/bevacizumab"],"companies":[{"name":"American Society of Clinical Oncology","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T19:42:21.410Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.485Z"}},"durationMs":41191,"modelName":"glm-4.7"}}